Skip to main content

Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC

Proton therapy not superior to IMRT in locally advanced NSCLC

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Roelofs E, Engelsman M, Rasch C et al (2012) Results of a Multicentric in Silico Clinical Trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 7:165–176

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Higgins KA, O’Connell K, Liu Y et al (2017) National Cancer Database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 97:128–137

    Article  PubMed  Google Scholar 

  3. 3.

    Wink KCJ, Roelofs E, Charles SB II et al (2018) Photons, protons or carbon ions for stage I non-small cell lung cancer: results of the multicentric ROCOCO in silico study. Radiother Oncol. https://doi.org/10.1016/j.radonc.2018.02.024

    PubMed  Article  Google Scholar 

  4. 4.

    Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. 5.

    Senan S, Brade A, Wang LH et al (2016) PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:953–962

    Article  PubMed  CAS  Google Scholar 

  6. 6.

    Kong F, Ten Haken RK, Schipper M et al (2017) Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol 3:1358–1365

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Glimelius B, Montelius A (2007) Proton beam therapy – do we need the randomised trials and can we do them? Radiother Oncol 83:105–109

    Article  PubMed  Google Scholar 

  8. 8.

    Bentzen SM (2008) Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol 86:142–147

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Goitein M, Cox JD (2008) Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 26:175–176

    Article  PubMed  Google Scholar 

  10. 10.

    Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M (2013) Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 107:267–273

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Lühr A, von Neubeck C, Krause M, Troost EGC (2018) Relative biological effectiveness in proton beam therapy – current knowledge and future challenges. Clin Transl Radiat Oncol 9:35–41

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Kadane JB, Seidenfeld T (1990) Randomization in a bayesian perspective. J Stat Plan Inference 25:329–345

    Article  Google Scholar 

  13. 13.

    Cheng Y, Shen Y (2005) Bayesian adaptive designs for clinical trials. Biometrika 92:633–646

    Article  Google Scholar 

  14. 14.

    Yin G, Lam CK, Shi H (2017) Bayesian randomized clinical trials: from fixed to adaptive design. Contemp Clin Trials 59:77–86

    Article  PubMed  Google Scholar 

  15. 15.

    Hoffmann AL, Troost EGC, Huizenga H, Kaanders JHAM, Bussink J (2012) Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial. Int J Radiat Oncol Biol Phys 83:1596–1602

    Article  PubMed  Google Scholar 

  16. 16.

    Kesarwala AH, Ko CJ, Ning H et al (2015) Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer 16:237–244

    Article  PubMed  Google Scholar 

  17. 17.

    Register SP, Zhang X, Mohan R, Chang JY (2011) Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 80:1015–1022

    Article  PubMed  Google Scholar 

  18. 18.

    Zhang X, Li Y, Pan X et al (2010) Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 77:357–366

    Article  PubMed  Google Scholar 

  19. 19.

    Chang JY, Zhang X, Knopf A et al (2017) Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys 99:41–50

    Article  PubMed  Google Scholar 

  20. 20.

    Jakobi A, Perrin R, Knopf A, Richter C (2018) Feasibility of proton pencil beam scanning treatment of free-breathing lung cancer patients. Acta Oncol 57:203–210

    Article  PubMed  Google Scholar 

  21. 21.

    Grassberger C, Dowdell S, Sharp G, Paganetti H (2015) Motion mitigation for lung cancer patients treated with active scanning proton therapy. Med Phys 42:2462–2469

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Zschaeck S, Simon M, Löck S et al (2016) PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. Trials 17:543

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Steffen Löck.

Ethics declarations

Interessenkonflikt

A. Dutz, E.G.C. Troost und S. Löck geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Liao Z, Lee JJ, Komaki R, Gomez DR et al (2018) Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2017.74.0720

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dutz, A., Troost, E.G.C. & Löck, S. Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC. Strahlenther Onkol 194, 790–793 (2018). https://doi.org/10.1007/s00066-018-1321-3

Download citation